<DOC>
	<DOC>NCT01434888</DOC>
	<brief_summary>The objective of this study is to investigate the pharmacokinetics, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC) to those of preservative-free tafluprost 0.0015% and timolol 0.5% eye drops in healthy volunteers.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops</brief_title>
	<detailed_description />
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Aged 18 to 45 years Good general health Meet best corrected ETDRS visual acuity Significant systemic or ocular disease History of eye surgery, including refractive surgery Allergy or hypersensitivity to study drug Low heart rate (&lt;50 bpm) Clinically relevant low blood pressure Asthma Bradycardia Use of contact lenses within one week prior to screening or during the study Clinically significant obesity (body mass index &gt; 30 kg/m2) Blood donation within 2 months prior to screening Females who are pregnant or lactating and females not using adequate contraceptives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>